AstraZeneca Truqap, Faslodex combo approved in EU for advanced ER-positive breast cancer Ruchika Sharma21 Jun 2024 10:00 AM ISTCambridge: AstraZeneca has announced that Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the...
Roche Inavolisib gets USFDA priority review for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation Ruchika Sharma29 May 2024 11:30 AM ISTBasel: Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application and granted Priority...
Roche gets USFDA Breakthrough Therapy Designation for Inavolisib for breast cancer with mutation Ruchika Sharma21 May 2024 2:30 PM ISTBasel: Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an...
AstraZeneca Truqap plus Faslodex recommended for approval in EU by CHMP for advanced ER-positive breast cancer Ruchika Sharma1 May 2024 11:30 AM ISTCambridge: AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the...
AstraZeneca Truqap plus Faslodex gets nod in Japan for advanced HR-positive breast cancer Ruchika Sharma31 March 2024 2:30 PM ISTCambridge: AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult...
Roche Gets CDSCO Panel Nod to Study anti-cancer Drug Giredestrant for Breast Cancer Dr. Divya Colin7 Jan 2024 6:00 PM ISTNew Delhi: The drug major Roche has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Truqap plus Faslodex approved in US for advanced HR-positive breast cancer: AstraZeneca Ruchika Sharma18 Nov 2023 2:14 PM ISTCambridge: AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult...
USFDA grants priority review to Capivasertib in combination with Faslodex for advanced HR-positive breast cancer: AstraZeneca Ruchika Sharma13 Jun 2023 11:20 AM ISTBreast cancer is the most common cancer worldwide, with an estimated 2.3 million patients diagnosed each year.
Capivasertib addition to fulvestrant improves progression-free survival in patients with advanced (HR)-positive breast cancer Isra Zaman9 Dec 2022 9:45 AM ISTPatients with HR-positive, HER2-negative breast cancer are commonly treated in the first line with an endocrine therapy-such as an aromatase...
Zydus Cadila breast cancer drug Fulvestrant gets USFDA okay Medical Dialogues Bureau31 July 2021 1:33 PM ISTZydus Cadila said Fulvestrant Injection will be manufactured at the group's formulation manufacturing facility at Zydus Biologics, Ahmedabad.
